These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 35837349)

  • 1. Targeting
    Ji J; Wang C; Fakih M
    Onco Targets Ther; 2022; 15():747-756. PubMed ID: 35837349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity and resistance to KRAS
    Ye W; Lu X; Qiao Y; Ou WB
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189108. PubMed ID: 38723697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer.
    Miyashita H; Hong DS
    J Cancer Immunol (Wilmington); 2024; 6(2):62-69. PubMed ID: 39175850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of KRAS
    Piazza GA; Chandrasekaran P; Maxuitenko YY; Budhwani KI
    Front Oncol; 2024; 14():1412435. PubMed ID: 38978742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adagrasib: a novel inhibitor for
    Guo MZ; Marrone KA; Spira A; Rosner S
    Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
    Palma G; Khurshid F; Lu K; Woodward B; Husain H
    NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
    Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
    Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting
    Ros J; Vaghi C; Baraibar I; Saoudi González N; Rodríguez-Castells M; García A; Alcaraz A; Salva F; Tabernero J; Elez E
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The path to the clinic: a comprehensive review on direct KRAS
    Kwan AK; Piazza GA; Keeton AB; Leite CA
    J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
    Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
    BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
    Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
    Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
    Iska S; Alley EW
    Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting KRAS in Colorectal Cancer.
    Wang C; Fakih M
    Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent inhibitor targets KRas
    Li HY; Qi WL; Wang YX; Meng LH
    Genes Dis; 2023 Mar; 10(2):403-414. PubMed ID: 37223497
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer.
    Qunaj L; May MS; Neugut AI; Herzberg BO
    Front Oncol; 2023; 13():1252516. PubMed ID: 37790760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.